Lyell Immunopharma Inc
LYEL
查看详细走势图
35.090USD
-3.510-9.09%
收盘 12/26, 16:00（美东）报价延迟15分钟
677.03M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-9.09%
5天
+5.28%
1月
+43.75%
6月
+292.51%
今年开始到现在
+174.14%
1年
+169.92%
查看详细走势图
TradingKey Lyell Immunopharma Inc股票评分
单位: USD 更新时间: 2025-12-26操作建议
Lyell Immunopharma Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名107/404位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价27.33。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Lyell Immunopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
持有
评级
27.333
目标均价
-3.62%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Lyell Immunopharma Inc亮点
亮点风险
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
业绩增长期
公司处于发展阶段，最新年度总收入61.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入61.00K美元
估值合理
公司最新PE估值-1.54，处于3年历史合理位
机构减仓
最新机构持股9.93M股，环比减少2.96%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值779.00K
Lyell Immunopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Lyell Immunopharma Inc简介
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
公司代码LYEL
公司Lyell Immunopharma Inc
CEOSeely (Lynn)
网址https://lyell.com/
常见问题
Lyell Immunopharma Inc(LYEL)的当前股价是多少？
Lyell Immunopharma Inc(LYEL)的当前股价是 35.090。
Lyell Immunopharma Inc的股票代码是什么？
Lyell Immunopharma Inc的股票代码是LYEL。
Lyell Immunopharma Inc股票的52周最高点是多少？
Lyell Immunopharma Inc股票的52周最高点是45.000。
Lyell Immunopharma Inc股票的52周最低点是多少？
Lyell Immunopharma Inc股票的52周最低点是7.650。
Lyell Immunopharma Inc的市值是多少？
Lyell Immunopharma Inc的市值是677.03M。
Lyell Immunopharma Inc的净利润是多少？
Lyell Immunopharma Inc的净利润为-342.99M。
现在Lyell Immunopharma Inc(LYEL)的股票是买入、持有还是卖出？
根据分析师评级，Lyell Immunopharma Inc(LYEL)的总体评级为持有，目标价格为27.333。
Lyell Immunopharma Inc(LYEL)股票的每股收益（EPS TTM）是多少
Lyell Immunopharma Inc(LYEL)股票的每股收益（EPS TTM）是-22.785。
相关品种
